Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA) (S26.009)

Sheng-Han Kuo; Liana Rosenthal; Gilbert L’Italien; Michele Potashman; Melissa Beiner; Victoria Wirtz; Irfan Qureshi; Susan Perlman; Vladimir Coric; Jeremy Schmahmann

doi:10.1212/wnl.0000000000217020

June 9, 2026Neurology

Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA) (S26.009)

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of troriluzole in delaying the time to progression to wheelchair in spinocerebellar ataxia patients.
Analyzed patients treated with troriluzole over 3 years.
Compared outcomes with untreated external natural history cohorts.
Troriluzole-treated subjects show a significant delay in progression to wheelchair compared to controls.
Specific metrics on event rates and statistical significance are needed for detailed findings.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Examine the treatment benefits of troriluzole over 3 years in patients with spinocerebellar ataxia (SCA) with a time to progression to wheelchair analysis in troriluzole-treated subjects vs untreated external controls.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kuo et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf32afaef96ed7f055a3b https://doi.org/10.1212/wnl.0000000000217020

View at Publisher

Ask AI

Bookmark

Share

Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA) (S26.009)

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA) (S26.009)

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading